Clinical trial · Interventional
uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
Phase II Trial: uPAR-PET/MR in Patients With Newly Diagnosed Prostate Cancer; Non-invasive Characterization of Tumor Aggressiveness
NCT03307460CI-TRIAL-00048453unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NOTA-AE105 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- uPAR PET/MRI
- description
- 68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
- interventionNames
- Drug: 68Ga-NOTA-AE105
Primary outcomes (1)
- measure
- Correlation with Gleason Score
- timeFrame
- 3 months after PET/MRI
- description
- Correlate the uptake of 68Ga-NOTA-AE105 with Gleason Score obtained from biopsy material.
Secondary outcomes (2)
- measure
- Prognostic value
- timeFrame
- 3 years from PET/MRI
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically verified prostate cancer * Capable of understanding written information and giving informed consent * Planned to enter active surveillance strategy or undergo therapy with curative intent (surgery or radiotherapy) Exclusion Criteria: * Obesity (Body weight over 140 kg) * Known allergy to 68-Ga-NOTA-AE105 * Metallic components in the body that contradicts MRI scan * Severe claustrophobia making the person unable to complete an MRI scan
References
Publications (0)
Data not yet available
No reference posted for this study.